How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,738 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Brodalumab for treating moderate to severe plaque psoriasis

Brodalumab for treating moderate to severe plaque psoriasis Brodalumab for treating moder Brodalumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 21 March 2018 nice.org.uk/guidance/ta511 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Brodalumab for treating moderate to severe plaque psoriasis (TA511) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20Contents Contents 1 Recommendations 4 2 Information about brodalumab 6 3

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

22. Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum. (Full text)

Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum. S100A8 and S100A9 proteins are highly upregulated in patients with psoriasis and have been proposed as potential biomarkers for psoriasis. The present study was designed to analyze the effect of narrowband ultraviolet B therapy on these proteins. S100A8, S100A9 gene (...) expression and S100A8/A9 heterocomplex protein levels were analyzed in lesional and non-lesional skin before and after narrowband-UVB treatment in patients with chronic plaque type psoriasis. In addition, disease severity was measured by psoriasis area and severity index (PASI) and serum protein levels of S100A8/A9 were repeatedly analyzed. Narrowband-UVB treatment significantly reduced S100A8, S100A9 gene expression and S100A8/A9 protein levels in lesional skin while serum levels showed no significant

2019 PLoS ONE PubMed

25. Psoriasis

Psoriasis Psoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Psoriasis Last reviewed: February 2019 Last updated: January 2019 Summary Lesions are red, inflamed, silvery-white scaly, and circumscribed papules and plaques; often affecting elbows, knees, extensor limbs, and scalp, and, less commonly, nails, ear, and umbilical region. Typically lifelong, with a fluctuating course of exacerbations and remission (...) of lesions, which may be aggravated by genetic, infectious, emotional, and environmental factors. Diagnosis is usually clinical. Mild or limited psoriasis is treated with topical corticosteroids and/or vitamin D analogues. Moderate to severe and/or extensive psoriasis may require phototherapy, and systemic agents such as oral retinoids, methotrexate, biological agents, ciclosporin or apremilast. Definition Psoriasis is a chronic inflammatory skin disease characterised by erythematous, circumscribed scaly

2018 BMJ Best Practice

26. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Adalimumab, etanercept and ustekinumab all offer some benefits for plaque psoriasis in children and young people but their cost per QALY is highly uncertain. {{author}} {{($index , , , , , , , & . Ana Duarte 1 , Teumzghi Mebrahtu 2 , Pedro Saramago Goncalves 1 , Melissa Harden 2 , Ruth Murphy 3 , Stephen Palmer 1 , Nerys

2017 NIHR HTA programme

27. Certolizumab pegol (Cimzia) - the treatment of moderate to severe plaque psoriasis

Certolizumab pegol (Cimzia) - the treatment of moderate to severe plaque psoriasis 1 Published 08 April 2019 1 SMC2132 certolizumab pegol 200mg solution for injection in pre-filled syringe and pen (Cimzia®) UCB Pharma Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) certolizumab pegol (Cimzia ® ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra- indication to these treatments. Certolizumab pegol has shown a similar reduction in the signs and symptoms of psoriasis

2019 Scottish Medicines Consortium

28. Tildrakizumab (Ilumetri) - treatment of adults with moderate to severe plaque psoriasis

Tildrakizumab (Ilumetri) - treatment of adults with moderate to severe plaque psoriasis Published 12 August 2019 1 SMC2167 tildrakizumab 100mg solution for injection in pre- filled syringe (Ilumetri®) Almirall Limited 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) tildrakizumab (Ilumetri ® ) is accepted for restricted use within NHSScotland. Indication under review: The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. SMC restriction: for use in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments. Tildrakizumab was superior to placebo in improving the signs and symptoms

2019 Scottish Medicines Consortium

29. Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety

Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety | CADTH.ca Find the information you need Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety Last updated (...) : April 3, 2018 Project Number: RC0979-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of cyclosporine for moderate to severe plaque psoriasis in adults? What is the short and long-term safety of cyclosporine for moderate to severe plaque psoriasis in adults? Key Message Three systematic reviews, two randomized-controlled trials (RCTs), and nine non-randomized studies of safety outcomes formed

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

30. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities - Journal of the American Academy of Dermatology Email/Username: Password: Remember me Search JAAD & JAAD Case Reports Search Terms Search within Search Access provided by Volume 80, Issue 4, Pages 1073–1113 Joint AAD-NPF guidelines of care (...) for the management and treatment of psoriasis with awareness and attention to comorbidities x Craig A. Elmets Affiliations University of Alabama, Birmingham, Alabama , MD ((Co-Chair)) a , x Craig L. Leonardi Affiliations Central Dermatology, St. Louis, Missouri , MD b , x Dawn M.R. Davis Affiliations Mayo Clinic, Rochester, Minnesota , MD c , x Joel M. Gelfand Affiliations University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania , MD, MSCE d , x Jason Lichten Affiliations National

2019 American Academy of Dermatology

31. Skyrizi - risankizumab - Psoriasis, moderate to severe plaque

Skyrizi - risankizumab - Psoriasis, moderate to severe plaque risankizumab | CADTH.ca Find the information you need risankizumab risankizumab Last Updated: June 24, 2019 Result type: Reports Project Number: SR0583-000 Product Line: Generic Name: risankizumab Brand Name: Skyrizi Manufacturer: AbbVie Corporation Indications: Psoriasis, moderate to severe plaque Manufacturer Requested Reimbursement Criteria 1 : Reimburse in a manner similar to other biologics for the treatment of moderate (...) -to-severe plaque psoriasis. Treatment should be discontinued if a response (PASI75) to treatment with risankizumab has not been demonstrated after 16 weeks. Submission Type: New Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: May 28, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

32. Risankizumab (Skyrizi) - plaque psoriasis

Risankizumab (Skyrizi) - plaque psoriasis 1 Published 07 October 2019 1 SMC2196 risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®) AbbVie Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission risankizumab (Skyrizi ® ) is accepted for restricted (...) use within NHSScotland. Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments. Risankizumab was superior to placebo, a tumour necrosis factor antagonist, and an interleukin 12/23 antagonist in improving

2019 Scottish Medicines Consortium

33. Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 EMA/CHMP/520007/2018 Committee for Medicinal (...) (cell) NKIPC Non- Key in process control Assessment report EMA/CHMP/520007/2018 Page 6/128 NKPP Non-key process parameter NMR Nuclear magnetic resonance NSD Needle safety device NZW New Zealand White OOS Out of specification PACMP Post approval change management protocol PAR Proven Acceptable Ranges PASI Psoriasis area and severity index PASI50/75/90/100 Reduction of the PASI score by 50%, 75%, 90% or more or 100% PASI50/PASI75 Reduction of 50%/75% or more of the Psoriasis Area and Severity Index

2018 European Medicines Agency - EPARs

34. Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 (...) Neutralizing antibody NK Natural Killer (cell) NKIPC Non- Key in process control Assessment report EMA/CHMP/519681/2018 Page 6/128 NKPP Non-key process parameter NMR Nuclear magnetic resonance NSD Needle safety device NZW New Zealand White OOS Out of specification PACMP Post approval change management protocol PAR Proven Acceptable Ranges PASI Psoriasis area and severity index PASI50/75/90/100 Reduction of the PASI score by 50%, 75%, 90% or more or 100% PASI50/PASI75 Reduction of 50%/75% or more

2018 European Medicines Agency - EPARs

35. Tildrakizumab (Ilumetri) - plaque psoriasis

Tildrakizumab (Ilumetri) - plaque psoriasis Ilumetri | European Medicines Agency Search Search Menu Ilumetri tildrakizumab Table of contents Authorised This medicine is authorised for use in the European Union. Overview Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable. Ilumetri contains (...) the tildrakizumab. Expand section Collapse section How is Ilumetri used? Ilumetri can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating plaque psoriasis. Ilumetri is available as a solution in pre-filled syringes for injection under the skin. The recommended dose is one 100 mg injection, followed by a further dose after 4 weeks and then an injection every 12 weeks. The dose may be increased to 200 mg in certain patients, for example

2018 European Medicines Agency - EPARs

36. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Psoriasis Zessly is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA. The legal basis for this application refers to: Article 10(4) of Directive 2001/83/EC

2018 European Medicines Agency - EPARs

37. Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis (Full text)

Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis Psoriasis is a frequent inflammatory skin disease affecting ~2%-3% of the population in western countries. Scaling of the psoriatic lesions is the most impairing symptom in patients with psoriasis. In contrast to conventional keratolytic (...) treatment concepts containing salicylic acid or urea, a dimeticone-based medical device (Loyon®) removes scales in a physical way without any pharmacological effect.To assess the efficacy and tolerability of a dimeticone-based medical device in removal of scales in patients with psoriasis corporis/capitis under real-life conditions.Forty patients with psoriasis capitis or corporis were included and received once-daily treatments for 7 days. Clinical assessment of the psoriasis area severity index score

2017 Psoriasis (Auckland, N.Z.) PubMed

38. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Full text)

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs (...) ) have compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments remains unclear due to the limited number of trials comparing them directly head to head, which is why we chose to conduct a network meta-analysis.To compare the efficacy and safety of conventional systemic agents (acitretin, ciclosporin, fumaric acid esters, methotrexate), small molecules (apremilast, tofacitinib, ponesimod), anti-TNF alpha (etanercept

2017 Cochrane PubMed

39. Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. (PubMed)

Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. In the U.S., black patients are less likely than whites to receive biologic treatment for their psoriasis. We conducted a qualitative freelisting study to identify patient-generated factors that may explain this apparent racial disparity in psoriasis treatment by comparing the perceptions of biologics and other psoriasis therapies between white and black adults with psoriasis (...) . Participants included 68 white and black adults with moderate to severe psoriasis who had and had not received biologic treatment. Each participant was asked to list words in response to verbal probes querying five psoriasis treatments: self-injectable biologics, infliximab, methotrexate, apremilast, and phototherapy. Salience scores indicating the relative importance of each word were calculated, and salient words were compared across each race-treatment group. Participants who had experience

2019 Journal of Investigative Dermatology

40. Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. (PubMed)

Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. To assess ocular abnormalities in psoriatic patients (new-cases versus patients under treatment) in comparison with healthy controls.A total of 200 psoriatic patients and 100 healthy controls were enrolled in this prospective, observational study. The demographic data of the individuals were recorded. Dermatological and ophthalmologic examinations were (...) the groups. Although no significant differences were found between the ocular findings of new cases and patients under treatment, ocular findings in cases under treatment were associated with the type of treatment and more frequent in those treated with methotrexate, followed by acitretin and biologic drugs.Ocular surface problems in psoriatic patients are more common than previously thought; in addition to the role of treatment modalities, psoriasis itself and a probable systemic inflammation may play

2019 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>